All In Biotech

Drug Trial Radar · NCT04847102

A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above

A Global, Multi-center, Randomized, Double-Blind, Placebo-controlled, Phase III Clinical Study to Evaluate the Protective Efficacy, Safety and Immunogenicity of SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine in Population Aged 18 Years and Older

Last checked: Nov 20, 2026Latest source record: Nov 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 28,000 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

28,000

Planned (sponsor's estimate)

Start

Jul 22, 2021

Primary completion

Nov 30, 2021

Study completion May 30, 2023

Sponsor

Lead sponsor
Walvax Biotechnology Co., Ltd.Industry
Sponsor type
Industry
Collaborators
Abogen Biosciences Co. Ltd.; Yuxi Walvax Biotechnology Co., Ltd.
First posted
Apr 15, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Approximately 28,000 subjects will be enrolled in this trial. Eligible subjects will be stratified by age (\<60 years of age and ≥60 years of age, the proportion of elderly people ≥60 years old is planned to be ≥25%) and randomly assigned into the study group and the control group at a ratio of 1:1 (14,000 in each group) to be intramuscularly administered with the investigational vaccine or placebo in a 2-dose regimen at an interval of 28 days. The experimental vaccines will be cross-vaccinated after available data of the investigational vaccine show that expected efficacy and good safety have been achieved (i.e., subjects in the study group will be vaccinated with placebo and those in the control group will be vaccinated with the investigational vaccine in the same schedule as stated above ). After the completion of the second dose for crossover vaccination, subjects will be followed up for 12 months for safety observation. An immunogenicity subgroup (n≥3000) and a reactogenicity subgroup (n≥6000) will also be included in this trial to evaluate the humoral immunity induced by the investigational vaccine and the solicited adverse events observed within 7 days post immunization. All enrolled subjects will be followed up for the evaluation of protective efficacy as well, which will be primarily characterized by the incidence rate (person-year) of COVID-19 cases collected from 14 days after complete series. Adverse events will be collected over 0-28 days after each vaccination and serious adverse events will be collected from Dose 1 through 12 months post complete series.

Conditions

  • COVID-19
  • SARS-CoV-2

Interventions

  • SARS-CoV-2 mRNA VaccineBiological

    The SARS-CoV-2 mRNA Vaccine is formulated by encapsulating the mRNA, which encodes the receptor-binding domain (RBD) of spike glycoprotein (S protein) of SARS-CoV-2 and is transcribed in-vitro by the corresponding DNA template, in lipid nanoparticles (LNPs). This vaccine is presented as a white to off-white dispersion for injection. Active substances: mRNA encoding the RBD of the S protein of SARS-CoV-2. The vaccine is supplied in single-dose pre-filled syringe with 0.5 mL dispersion for intramuscular injection. Each dose (0.5 mL) of the vaccine contains: 15 μg of mRNA encoding the RBD of the spike glycoprotein (S protein) of SARS-CoV-2, 0.339 mg of total lipids (including lipid 9001, cholesterol, DSPC, DMG-PEG2000).

  • PlaceboBiological

    0.9% sodium chloride solution, 0.5 mL/vial

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary efficacy endpoint as measured by the incidence rate (person-year) of COVID-19 casesTime frame: From 14 days after complete series
  2. Primary safety endpoint as measured by the incidence rates of adverse eventsTime frame: Within 28 days post each vaccination
  3. Primary safety endpoint as measured by the incidence rates of serious adverse eventsTime frame: At 7 days post each vaccination

Locations

12 sites in 2 countries. Site status is shown where the registry gives one.

  • Persahabatan Hospital

    Jakarta, Indonesia · Recruiting

  • Puskesmas Duren Sawit

    Jakarta, Indonesia · Recruiting

  • Puskesmas Kalideres

    Jakarta, Indonesia · Recruiting

  • Puskesmas Kebayoran Lama

    Jakarta, Indonesia · Recruiting

  • Puskesmas Pulogadung

    Jakarta, Indonesia · Recruiting

  • Centro de Investigación Clínica del Pacifico S.A. de C.V. (CICPA)

    Acapulco, Mexico · Recruiting

  • Centro de Investigación y Avances Médicos Especializados (CIAME)

    Cancún, Mexico · Recruiting

  • Centro de Especialidades Médicas Aplicadas

    Mexico City, Mexico · Recruiting

  • Instituto Nacional de Pediatría (INP)

    Mexico City, Mexico · Recruiting

  • Oaxaca site management organization (OSMO)

    Oaxaca City, Mexico · Recruiting

  • Asociación Mexicana para la investigación clínica, A.C. (AMIC)

    Pachuca, Mexico · Recruiting

  • Oncológico Potosino

    San Luis Potosí City, Mexico · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.